MANCHESTER, England — Even when C-reactive protein (CRP) levels are normal, patients with seropositive rheumatoid arthritis (RA) could still be experiencing significant disease that persists over time ...
In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.
“High-sensitivity CRP has been shown to be an independent marker of risk in addition to and in some cases over and above all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results